At physiological doses (100-300 mcg/day):

• No discernible subjective effect in iodine-replete users. This is the expected baseline.
• In iodine-deficient users (e.g., switched to non-iodized salt, no seafood, no dairy), gradual symptom relief over 4-12 weeks may occur — improved energy, reduced cold intolerance, reduced "brain fog," improved hair quality, improved cycle regularity (in women). But these symptoms have many other causes (iron, B12, sleep, thyroid disease independent of iodine), so the subjective "iodine fixed me" attribution is unreliable.

At moderate doses (1-5 mg/day, e.g., one drop Lugol's 5%):

• ~30-60% of users report no acute effect.
• Some users report transient energy increase + metallic taste in first week.
• A small fraction (~10-15%) develop "iodism" — metallic taste, headache, salivary gland swelling (parotitis), increased mucus, GI upset, brassy taste, occasional skin acneiform eruption.

At megadose (12.5-50 mg/day Lugol's, Iodoral, kelp megadose):

• Acute: metallic taste, increased salivation, headache, GI upset common in first week.
• Subacute (1-12 weeks): iodism symptoms more prominent — acne flare, persistent metallic taste, sialadenitis, fatigue, brain fog (paradoxical if iodine was supposed to fix this).
• Chronic (months): potential development of subclinical or overt hypothyroidism (fatigue, weight gain, cold intolerance, hair loss — exactly the symptoms the protocol was sold to fix); alternatively, hyperthyroidism if autonomous nodules present (palpitations, weight loss, heat intolerance, anxiety, insomnia).
• A significant subset (online forum reports + case literature): Hashimoto's flare, with sharp TPO antibody titer rise and worsening hypothyroid symptoms.

At emergency-prophylaxis dose (KI 130 mg single dose):

• Transient metallic taste, GI upset, mild nausea. Generally well-tolerated as a one-time exposure.
• Repeated daily use of 130 mg/day Wolff-Chaikoff-blocks thyroid synthesis durably and is not an indication for general supplementation.

Honest variability: subjective experience of iodine is highly dependent on (a) baseline iodine status, (b) underlying thyroid disease (often subclinical), (c) selenium status, (d) genetic susceptibility (HLA, TPO polymorphisms). The same dose that feels neutral to one user can cause a Hashimoto's flare in another.

• No tolerance in the receptor-pharmacology sense — iodine is a substrate, not a ligand. The body's iodine pool turnover is on the order of 100 days, and homeostatic regulation operates through NIS expression, TSH feedback, and Wolff-Chaikoff escape.
• No cycling needed at physiological doses (100-300 mcg/day). Continuous use across decades is the physiological norm — that's what salt iodization is.
• Cycling in megadose protocols is sometimes proposed (e.g., "pulse Lugol's 50 mg for 3 months, then maintenance 12.5 mg") but this does not mitigate dependence-style concerns because the issue isn't pharmacological tolerance — it's cumulative thyroid damage and autoimmune induction.
• Discontinuation after megadose protocol: thyroid function should be checked. Iodine-induced hypothyroidism typically reverses within 2-8 weeks of stopping; Jod-Basedow hyperthyroidism reverses similarly. Hashimoto's flare-induced TPO antibody titers may take longer to normalize and sometimes do not return fully to baseline.

Synergistic with

• Selenium (100-200 mcg/day, ideally as selenomethionine): Mandatory co-factor for iodine utilization. Deiodinase enzymes (T4 → T3) are selenoproteins. Glutathione peroxidase (which protects thyrocytes from H₂O₂ generated during iodination) is a selenoprotein. Adequate selenium status reduces autoimmune thyroiditis risk of iodine exposure (Gärtner 2002, multiple Hashimoto's trials). If supplementing iodine above 300 mcg/day, pair with selenium. Brazil nuts (2-3/day ≈ 100-200 mcg selenium) is a clean dietary route.
• L-Tyrosine: Substrate that gets iodinated to form T4/T3. Supplementation does not affect thyroid hormone output in iodine-replete users (the rate-limiting step is iodine + TSH, not tyrosine availability), but a normal protein intake is presupposed.
• Iron (ferritin 50-100 ng/mL): TPO is a heme protein; iron deficiency impairs TPO activity and worsens iodine-deficiency-related hypothyroidism. Correct iron deficiency in any iodine-related workup.
• Zinc (8-15 mg/day): Required for thyroid hormone receptor and pituitary TSH function. Low zinc worsens hypothyroid symptoms in deficient users.
• Vitamin D3: Low 25(OH)D is associated with higher Hashimoto's antibody titers; correction may reduce autoimmune severity.
• Vitamin A: Required for TSH receptor function and thyroid hormone metabolism; severe vitamin A deficiency mimics iodine deficiency.

Avoid stacking with

• Amiodarone: Each 200 mg tablet contains 74 mg iodine (~493× RDA). Co-supplementing iodine is contraindicated. Amiodarone is itself a leading cause of iodine-induced thyroid dysfunction (~14-18% incidence of either hypothyroidism or thyrotoxicosis on chronic amiodarone).
• Lithium: Blocks thyroid hormone release; co-iodine supplementation can produce unpredictable thyroid swings. Lithium-induced hypothyroidism is the classic context.
• Carbimazole, methimazole, propylthiouracil (PTU): Antithyroid drugs work by blocking TPO. Combining with iodine supplementation produces unpredictable hormone fluctuations. Should only be combined under endocrinology supervision (and the combo is sometimes used short-term presurgically).
• Soy isoflavones (high-dose): Goitrogenic; can interfere with TPO function in iodine-deficient users. In iodine-replete users, no clinically meaningful effect at typical dietary soy intake. Megadose soy isoflavone supplements + low iodine intake can produce subclinical hypothyroidism.
• Cruciferous vegetables (goitrogens — broccoli, cabbage, kale, raw): Theoretical concern at very high intake in iodine-deficient users; not relevant at normal dietary intake with adequate iodine.

Neutral / safe co-administration

• All standard biohacker stack components (creatine, magnesium, omega-3, NAC, multivitamin, vitamin D3, K2, B-complex, taurine, l-theanine, glycine, ashwagandha, rhodiola, BPC-157, modafinil at physiological doses, peptides) — no clinically meaningful iodine-related interactions at typical doses.

• Amiodarone: Massive iodine content (37% iodine by weight). Each 200 mg dose = 74 mg elemental iodine. Use of iodine supplements concurrently is contraindicated. Amiodarone-induced hypothyroidism (AIH, ~5-12%) and amiodarone-induced thyrotoxicosis (AIT type 1: Jod-Basedow in nodular goiter; AIT type 2: destructive thyroiditis) are well-characterized.
• Lithium: Inhibits thyroid hormone release. Iodine + lithium co-administration produces unpredictable thyroid dynamics; both drugs require TSH monitoring.
• Radiologic contrast media (iohexol, iopamidol, ioversol, etc.): Contain large iodine loads (50-300+ mg per scan). Single CT contrast bolus can precipitate Jod-Basedow in nodular goiter (~38% incidence over weeks-to-months). Discuss with physician before contrast in patients with thyroid nodules.
• ACE inhibitors, potassium-sparing diuretics: Potassium iodide adds potassium load. Generally clinically insignificant at supplemental doses; matters at KI 130 mg emergency doses.
• Antithyroid drugs (methimazole, PTU, carbimazole): Iodine supplementation antagonizes effect by providing more substrate; under endocrinology supervision, can be used short-term pre-thyroidectomy to shrink gland (Plummer's iodine, classic surgical pre-op).
• Radioactive iodine (¹³¹I, ¹²³I) therapy: Pre-procedure iodine restriction is mandated for 1-2 weeks; supplementation interferes with uptake of the radioisotope. Coordinate with nuclear medicine.
• Povidone-iodine topical: Large-area or prolonged use (e.g., chronic wound care, surgical scrubs in healthcare workers) produces meaningful systemic absorption. In pregnancy/lactation, neonates, and Hashimoto's, large-area povidone-iodine should be avoided when alternatives exist.
• Selenium: Beneficial interaction, see Stacking.
• Hormonal contraceptives, SSRIs, statins, common cardiac drugs: No clinically significant interaction.

Iodine is a substrate rather than a receptor ligand, so the pharmacogenomic landscape is about susceptibility to autoimmune and dysregulation phenotypes rather than dose response per se.

• HLA-DR3, HLA-DR5: Strong association with Hashimoto's thyroiditis susceptibility. Carriers exposed to high iodine intake have higher TPO antibody titers and faster progression to overt disease. Practical implication: if family history of Hashimoto's or Graves', take iodine megadose risk seriously even if asymptomatic. 23andMe / Promethease can identify HLA-DR variants.
• TPO polymorphisms: Variants associated with reduced TPO function modify iodine-deficiency tolerance (worse in deficient state) and iodine-excess autoimmune risk.
• NIS (SLC5A5) variants: Rare loss-of-function variants → congenital hypothyroidism with goiter responsive to high-dose iodine. Common variants have small effects on iodine handling.
• DUOX2 variants: Affect H₂O₂ generation and TPO activity; relevant in iodine-deficiency hypothyroidism susceptibility.
• Selenium-related (SELENOP, GPX, deiodinase variants): Modify iodine utilization efficiency; relevant in evaluating whether selenium supplementation is needed alongside iodine.
• Practical takeaway for users awaiting 23andMe results (Dylan's June 2026 panel): Look for HLA-DR variants, TPO polymorphisms, and known Hashimoto's-risk SNPs (e.g., CTLA4, PTPN22, CD40). If carrier of multiple autoimmune-risk variants, stay at or below RDA (150 mcg/day) unless dietary deficiency is documented.

Best routes for general users:

1. Dietary iodine via iodized salt + 2-3× weekly seafood + occasional dairy/eggs. Most reliable; no supplement needed.
2. 150 mcg in multivitamin if route 1 not viable (e.g., non-iodized-salt user, vegan/no-seafood).
3. Standardized kelp tablet (e.g., 150-300 mcg) as alternative to multivitamin.

Skip: Wild kelp without standardization (10-50× variability documented). Lugol's protocols without physician oversight. Iodoral 50 mg tablets unless specific indication.

Baseline (before any high-dose supplementation)

• TSH (target 0.4-4.0 mIU/L; some clinicians prefer 0.5-2.5 mIU/L)
• Free T4 (target 0.8-1.8 ng/dL)
• Free T3 (target 2.3-4.2 pg/mL)
• TPO antibodies (target <35 IU/mL; >100 = Hashimoto's confirmed; 35-100 borderline / monitor)
• Thyroglobulin antibodies (TgAb) (target <20 IU/mL; elevated = autoimmunity)
• Thyroglobulin (Tg) (interpret in context of TgAb; elevated Tg with low TgAb may indicate iodine deficiency)
• Urinary iodine, spot UI/Cr ratio (target 100-199 mcg/L = adequate; <100 = deficient; >300 = excess; >500 = excessive)
• Selenium, RBC selenium or whole-blood selenium (target ~120-150 ng/mL whole blood)
• Ferritin (target 50-150 ng/mL; iron deficiency impairs TPO function)
• 25(OH)D (target 30-60 ng/mL)

During use (only if supplementing above 500 mcg/day)

• TSH + fT4 quarterly for first year
• TPO antibodies at 3 and 6 months — flag any >20% titer increase
• Urinary iodine at 3 and 6 months — confirm absolute status

Watch for

• Rising TSH with normal fT4: subclinical iodine-induced hypothyroidism. Reduce dose.
• Falling TSH with normal fT4: subclinical hyperthyroidism / early Jod-Basedow. Reduce dose.
• Rising TPO antibody titer: autoimmune induction. Stop high-dose iodine, consider endocrinology referral.
• Symptoms of iodism (metallic taste, sialadenitis, acne, headache, GI upset): reduce dose.
• Symptoms of hypothyroidism (fatigue, weight gain, cold intolerance, hair loss, depression): reduce dose, check TSH.
• Symptoms of hyperthyroidism (palpitations, weight loss, heat intolerance, anxiety, tremor): stop, check TSH urgently.